Mosaic ImmunoEngineering Inc.

Mosaic ImmunoEngineering Inc. (OTC: CPMV) is a development-stage biotechnology company creating immunotherapy treatments for cancer with pipelines targeting both human oncology and veterinary applications. According to mosaicie.com, lead candidates MIE-101 and MIE-201 use plant virus-derived nanoparticles to stimulate targeted anti-tumor immune responses.

The company's canine immuno-oncology program provides a practical development path — companion animal studies offer scientific insight into human cancer immunity while creating an independent commercialization pathway for veterinary oncology treatments.

Founded by immunology and nanotechnology scientists, Mosaic ImmunoEngineering is advancing programs with grant funding and seeking strategic partners for its companion animal platform. Full pipeline details are at mosaicie.com.